Sign inJoin waitlistJoin the waitlist

Peter Schoettler

Program Director · Mayo Clinic College of Medicine and Science

Credentials: · · ·

History

Mayo Clinic College of Medicine and Science
Present
Mayo Clinic College of Medicine and Science
Present

Pediatric Hematology/Oncology
Mayo Clinic College of Medicine and Science
2018–2021
Pediatrics
University of California
2015–2018
University of Minnesota Medical School
2011–2015

Research

Type I pleuropulmonary blastoma: pathology and biology study of 51 cases from the international pleuropulmonary blastoma registry
The American Journal of Surgical Pathology · 2008 · 149 citations
Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in pleuropulmonary blastoma / DICER1 syndrome: a unique variant of the two-hit…
F1000Research · 2015 · 141 citations
DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies
Clinical Cancer Research · 2024 · 35 citations

Wendy Rhoades
5 papers
Ashley Hill
4 papers
Louis Dehner
4 papers
KS
Kris Ann Schultz
3 papers
Nadia Laack
3 papers
YM
Yoav Messinger
3 papers
AM
Anita Mahajan
2 papers
Elizabeth Mullen
2 papers
James Geller
2 papers
Jeffrey Dome
2 papers
Junne Kamihara
2 papers
Kenneth Chen
2 papers · 2 as a fellow

Clinical trials

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029